Indacaterol/glycopyrronium is cost-effective compared to salmeterol/fluticasone in COPD: FLAME-based modelling in a Swedish population

被引：0
|
作者：
Leif Bjermer
Job F. M. van Boven
Madlaina Costa-Scharplatz
Dorothy L. Keininger
Florian S. Gutzwiller
Karin Lisspers
Ronan Mahon
Petter Olsson
Nicolas Roche
机构：
[1] Skane University Hospital,Department of Respiratory medicine & Allergology
[2] Lund University,Department of General Practice
[3] Groningen Research Institute for Asthma and COPD (GRIAC),Unit of Pharmacoepidemiology & Pharmacoeconomics, Department of Pharmacy
[4] University Medical Center Groningen,Department of Public Health and Caring Sciences, Family Medicine and Preventive Medicine
[5] University of Groningen,Respiratory and Intensive Care Medicine
[6] University of Groningen,undefined
[7] Novartis Sverige AB,undefined
[8] Novartis Pharma AG,undefined
[9] Uppsala University,undefined
[10] Novartis Ireland Limited,undefined
[11] Cochin Hospital (AP-HP) and University Paris Descartes,undefined
来源：
Respiratory Research | / 18卷
关键词：
Chronic obstructive pulmonary disease; Indacaterol/glycopyrronium; Cost-effective; Exacerbation;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 42 条
  • [31] INDACATEROL/GLYCOPYRRONIUM SHOWS CONSISTENT IMPROVEMENT IN LUNG FUNCTION AND HEALTH-RELATED QUALITY OF LIFE VERSUS SALMETEROL/FLUTICASONE IN MODERATE-TO-VERY SEVERE COPD PATIENTS: THE FLAME STUDY
    Wedzicha, J. A.
    Roche, N.
    Larbig, M.
    Patalano, F.
    Thach, C.
    Fogel, R.
    Banerji, D.
    RESPIROLOGY, 2016, 21 : 116 - 116
  • [32] Indacaterol/glycopyrronium Improves Lung Function And Health Status Versus Salmeterol/fluticasone In Moderate-To-Very Severe COPD Patients Irrespective Of Prior Ics/laba/lama Therapy: The Flame Study
    Roche, N.
    Wedzicha, J. A.
    Donohue, J. F.
    Fucile, S.
    Yadao, A.
    Ayers, T.
    Maitra, S.
    Taylor, A. Fowler
    Fogel, R.
    Patalano, F.
    Banerji, D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [33] INDACATEROL/GLYCOPYRRONIUM IMPROVES LUNG FUNCTION AND HEALTH STATUS VERSUS SALMETEROL/FLUTICASONE IN MODERATE-TO-VERY SEVERE COPD PATIENTS IRRESPECTIVE OF PRIOR ICS/LABA/LAMA THERAPY: THE FLAME STUDY
    Roche, Nicolas
    Wedzicha, Jadwiga A.
    Donohue, James F.
    Fucile, Sebastian
    Yadao, Anthony
    Ayers, Tim
    Maitra, Samopriyo
    Fowlertaylor, Angel
    Fogel, Robert
    Patalano, Francesco
    Banerji, Donald
    RESPIROLOGY, 2017, 22 : 177 - 178
  • [34] Cost-effectiveness of indacaterol/glycopyrronium in comparison with salmeterol/fluticasone combination for patients with moderate-to-severe chronic obstructive pulmonary disease: a LANTERN population analysis from Singapore
    Tee, Augustine
    Chow, Wai Leng
    Burke, Colin
    Guruprasad, Basavarajaiah
    SINGAPORE MEDICAL JOURNAL, 2018, 59 (07) : 383 - 389
  • [35] INDACATEROL/GLYCOPYRRONIUM (IND/GLY) REDUCES THE RISK OF EXACERBATIONS VERSUS SALMETEROL/FLUTICASONE (SFC) IN MODERATE-TO-VERY SEVERE COPD PATIENTS IRRESPECTIVE OF PRIOR ICS/LABA/LAMA THERAPY: THE FLAME STUDY
    Wedzicha, Jadwiga A.
    Mezzi, Karen
    Ayers, Tim
    Thach, Chau
    Fogel, Robert
    Patalano, Francesco
    Banerji, Donald
    RESPIROLOGY, 2017, 22 : 84 - 84
  • [36] REDUCTION IN THE RATE AND RISK OF MODERATE OR SEVERE EXACERBATIONS WITH ONCE-DAILY INDACATEROL/GLYCOPYRRONIUM COMPARED WITH TWICE-DAILY SALMETEROL/FLUTICASONE IN A SUBSET OF GOLD GROUP D COPD PATIENTS WITH A HISTORY OF ≥2 EXACERBATIONS OR 1 HOSPITALIZATION: THE FLAME STUDY
    Banerji, D.
    Vogelmeier, C.
    Wedzicha, J.
    Donohue, J.
    Fucile, S.
    Yadao, A.
    Ayers, T.
    Thach, C.
    Olsson, P.
    Fowlertaylor, A.
    Fogel, R.
    Patalano, F.
    RESPIROLOGY, 2018, 23 : 74 - 74
  • [37] Once-Daily Indacaterol/glycopyrronium Reduces The Rate And Risk Of Moderate Or Severe Exacerbations Compared With Twice-Daily Salmeterol/fluticasone In A Subset Of Gold Group D COPD Patients With A History Of ≥2 Exacerbations Or 1 Hospitalization: The Flame Study
    Vogelmeier, C.
    Wedzicha, J.
    Donohue, J.
    Fucile, S.
    Yadao, A.
    Ayers, T.
    Thach, C.
    Taylor, A. Fowler
    Fogel, R.
    Patalano, F.
    Banerji, D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [38] Once-daily indacaterol/glycopyrronium (IND/GLY) reduces use of rescue medication versus twice-daily salmeterol/fluticasone (SFC) in patients with moderate-to-very severe COPD: results from the FLAME study
    Fogel, Robert
    Chapman, Kenneth R.
    Vogelmeier, Claus F.
    FowlerTaylor, Angel
    Ayers, Tim
    Thach, Chau
    Whelan, Sarah
    Clerkin, Karyn
    Patalano, Francesco
    Banerji, Donald
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
  • [39] LATE-BREAKING ABSTRACT: Indacaterol/glycopyrronium (IND/GLY) reduces the risk of exacerbations versus salmeterol/fluticasone (SFC) in moderate-to-very severe COPD patients irrespective of prior ICS/LABA/LAMA therapy: The FLAME study
    Wedzicha, Jadwiga
    Mezzi, Karen
    Ayers, Tim
    Thach, Chau
    Fogel, Robert
    Patalano, Francesco
    Banerji, Donald
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
  • [40] COST EFFECTIVENESS OF BUDESONIDE/FORMOTEROL VERSUS FLUTICASONE/SALMETEROL FROM A SWEDISH HEALTH CARE PERSPECTIVE BASED ON REAL-WORLD EFFECTIVENESS AND SAFETY IN PATIENTS WITH COPD
    Hedegaard, M.
    Janson, C.
    Lisspers, K.
    Stallberg, B.
    Johansson, G.
    Jorgensen, L.
    Larsson, K.
    VALUE IN HEALTH, 2013, 16 (03) : A235 - A235
12345